New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

aTyr Pharma, Inc. (ATYR) vs CytoMed Therapeutics Limited (GDTC)

aTyr Pharma, Inc. and CytoMed Therapeutics Limited are both Biotechnology companies. aTyr Pharma, Inc. and CytoMed Therapeutics Limited are of similar size ($9.2M and $9.0M). Across the 7 metrics below, aTyr Pharma, Inc. leads on 4 and CytoMed Therapeutics Limited on 3.

Valuation

Metric ATYR GDTC Biotechnology median
P/E n/m n/m 8.49
P/S 0.84 — 8.56
P/B 0.28 0.51 2.04
Price to free cash flow n/m n/m 23.84
EV/EBITDA 0.71 n/m 0.69
EV/Sales (3.53) — 8.00
Earnings yield (574.47%) (35.90%) (35.81%)
Free cash flow yield (469.71%) (0.43%) (25.41%)

Profitability

Metric ATYR GDTC Biotechnology median
Gross margin 100.00% — 70.18%
Operating margin (152.19%) — 0.00%
Net margin (155.18%) — 0.00%
Free cash flow margin (148.11%) — 0.00%
Return on equity (93.69%) — (51.58%)
Return on assets (64.07%) — (45.91%)
Return on invested capital 0.00% — 0.00%

Growth

Metric ATYR GDTC Biotechnology median
Revenue growth (TTM) — — 7.20%
EPS growth (last fiscal year) 6.98% (68.75%) 29.04%
Revenue growth, 5-year CAGR — — 9.54%
Net income growth, 5-year CAGR — — 0.00%

Health

Metric ATYR GDTC Biotechnology median
Debt to equity 0.00 80.30 0.00
Current ratio 3.05 2.64 4.79
Net debt to EBITDA 1.01 0.86 1.01

Dividend

Metric ATYR GDTC Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric ATYR GDTC Biotechnology median
Market cap 9.04m 9.15m 150.57m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack